Naslov
Folfiri vs folfiri + bevacizumab in first-line therapy of metastatic colorectal cancer: retrospective analysis of 81 patients in our institution

Autori
Rakušić, Zoran ; Jajac, Lana ; Juretić, Antonio ; Bišof, Vesna ; Mišir-Krpan, Ana ; Šantek, Fedor ; Bašić-Koretić, Martina ; Pleština, Stjepko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstract book of the 35th ESMO Congress ; u: Annals of Oncology 21 (2010)(S8) / - : ESMO Congress Scientific Committee, 2010, 217-217

Skup
ESMO Congress (35 ; 2010)

Mjesto i datum
Milano, Italija, 08.10.2010. - 12.10.2010

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
colorectal cancer; folfiri; bevacizumab

Sažetak
Neoadjuvant chemotherapy is standard of care for metastatic colorectal cancer. Bevacizumab prolongs pregression-free survival (PFS) and median survival when added to chemotherapy for first-line treatment of patients with metastatic colorectal disease. We retrospectivly analysed 81 patients with metastatic colorectal cancer who were treated in our institution from April 2007. to October 2009. The aim of this study was to access progression-free survival and evaluate toxicity of therapy. There were 49 male and 32 female patiens. As first line of chemotherapy for metastatic disease 37 patiens received FOLFIRI in standard doses (Group I) and 44 FOLFIRI + bevacizumab 5mg /kg (Group II). Mean age was 63.3 ± 9.8 (Group I) and 59.7 ± 9.8 (Group II), p=0.101. The most frequent site of metastatic disease was liver, 64.9% (Group I) and 72.7% (Group II), p=0.445. ECOG status was 0 (51.4%) and 1 (48.6%) in Group I, 65.9% and 34.1% in Group II, respectively, p=0.143. Average number of applied cycles was for FOLFIRI 9.6 ± 4.9 and for FOLFIRI + bevacizumab 13.6 ± 5.3, p=0.001. Confirmed time to progression for FOLFIRI (Group I) was 6.9 months and for FOLFIRI + bevacizumab (Group II) 10.2 months, p=0.003. In multivariate analisys (age, gender, ECOG status, site of metastatic disease, type of therapy) only significantly associated factor to outcome of treatment was type of therapy. Addition of bevacizumab to FOLFIRI showed improvement in PFS, HR=0.40, 95% CI 0.21-0.78, p=0.007. The most common side-effects in both groups were diarrhea, nausea, vomiting and neutropenia, but without statistically significant difference between groups. In Group II (FOLFIRI + bevacizumab) there were two tromboembolic events (4.5%), one intestinal perforation (2.3%), one bleeding from primary (2.3%), hypertension in four patients (9.0%). Our data suggest that combination of FOLFIRI + bevacizumab is signifficantly better combination than FOLFIRI in term of PFS, with acceptiable toxicity.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA